Cited 30 times in
Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강화평 | - |
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 이희승 | - |
dc.contributor.author | 정문재 | - |
dc.contributor.author | 조중현 | - |
dc.date.accessioned | 2019-01-15T16:55:57Z | - |
dc.date.available | 2019-01-15T16:55:57Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/166726 | - |
dc.description.abstract | AIM: To directly compare the efficacy and toxicity of standard-dose FOLFIRINOX (sFOLFIRINOX) and modified-dose FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) for pancreatic cancer. METHODS: One hundred and thirty pancreatic cancer patients who received sFOLFIRINOX (n = 88) or mFOLFIRINOX (n = 42) as their first-line chemotherapy from January 2013 to July 2017 were retrospectively reviewed. For efficacy analysis, the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated and compared using Pearson's chi-square test, Kaplan-Meier plot and log-rank test. The adverse events (AEs) were evaluated, and severe (≥ grade 3) AEs rates of the two groups were compared for toxicity analysis. RESULTS: The mFOLFIRINOX group included more female patients (30.7% vs 57.1%; P = 0.004) and older patients [age (median), 57 vs 63.5; P = 0.018] than the sFOLFIRINOX group. In the efficacy analysis, the ORR and DCR were not significantly different between the two groups (ORR: 39.8% vs 35.7%; P = 0.656; DCR: 80.7% vs 83.3%; P = 0.716). The median PFS and OS were also not different between the groups (PFS: 8.7 mo vs 8.1 mo, P = 0.272; OS: 13.9 mo vs 13.7 mo, P = 0.476). In the safety analysis with severe AEs, the rates of neutropenia (83.0% vs 66.7%; P = 0.044), anorexia (48.9% vs 28.6%; P = 0.029) and diarrhea (13.6% vs 0.0%; P = 0.009) were markedly lower in the mFOLFIRINOX group. CONCLUSION: mFOLFIRINOX showed comparable efficacy but better safety compared to sFOLFIRINOX. If clinically necessary, initiating FOLFIRINOX with 75% of the standard-dose can alleviate toxicity concerns without compromising efficacy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | China | - |
dc.publisher | 1948-5204 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Huapyong Kang | - |
dc.contributor.googleauthor | Jung Hyun Jo | - |
dc.contributor.googleauthor | Hee Seung Lee | - |
dc.contributor.googleauthor | Moon Jae Chung | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.identifier.doi | 10.4251/wjgo.v10.i11.421 | - |
dc.contributor.localId | A00100 | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A03349 | - |
dc.contributor.localId | A03602 | - |
dc.contributor.localId | A03912 | - |
dc.relation.journalcode | J03571 | - |
dc.identifier.eissn | 1948-5204 | - |
dc.identifier.pmid | 30487953 | - |
dc.subject.keyword | Adenocarcinoma | - |
dc.subject.keyword | Adverse event | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Dose modification | - |
dc.subject.keyword | FOLFIRINOX | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.contributor.alternativeName | Kang, Huapyong | - |
dc.contributor.affiliatedAuthor | 강화평 | - |
dc.contributor.affiliatedAuthor | 박승우 | - |
dc.contributor.affiliatedAuthor | 박정엽 | - |
dc.contributor.affiliatedAuthor | 방승민 | - |
dc.contributor.affiliatedAuthor | 송시영 | - |
dc.contributor.affiliatedAuthor | 이희승 | - |
dc.contributor.affiliatedAuthor | 정문재 | - |
dc.contributor.affiliatedAuthor | 조중현 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 421 | - |
dc.citation.endPage | 430 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, Vol.10(11) : 421-430, 2018 | - |
dc.identifier.rimsid | 57995 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.